Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
暂无分享,去创建一个
Jacques Fellay | David B. Goldstein | Kevin V. Shianna | Erin L. Heinzen | K. Shianna | D. Ge | D. Goldstein | J. Fellay | E. Heinzen | P. Qiu | A. Bertelsen | T. Urban | M. Sulkowski | J. McHutchison | J. Simon | Dongliang Ge | John G. McHutchison | Ping Qiu | A. Thompson | Alexander J. Thompson | Jason S. Simon | Thomas J. Urban | Arthur H. Bertelsen | Andrew J. Muir | Mark Sulkowski | A. Muir | J. Mchutchison
[1] G. Everson,et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. , 2009, The New England journal of medicine.
[2] G. McCaughan,et al. Intrahepatic interferon‐stimulated gene responses: Can they predict treatment responses in chronic hepatitis C infection? , 2007, Hepatology.
[3] Edward J Oakeley,et al. Interferon signaling and treatment outcome in chronic hepatitis C , 2008, Proceedings of the National Academy of Sciences.
[4] David B. Goldstein,et al. Population genetic structure of variable drug response , 2001, Nature Genetics.
[5] William M. Lee,et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. , 2004, Gastroenterology.
[6] Thomas Berg,et al. IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy , 2009, Nature Genetics.
[7] Edoardo Cervoni,et al. Hepatitis C , 1998, The Lancet.
[8] P. Killenberg,et al. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. , 2004, The New England journal of medicine.
[9] C. Rice,et al. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. , 2006, Gastroenterology.
[10] M. Whitlock. Combining probability from independent tests: the weighted Z‐method is superior to Fisher's approach , 2005, Journal of evolutionary biology.
[11] F. Chisari,et al. Lambda Interferon Inhibits Hepatitis B and C Virus Replication , 2005, Journal of Virology.
[12] D. Reich,et al. Principal components analysis corrects for stratification in genome-wide association studies , 2006, Nature Genetics.
[13] A. Lewis-Antes,et al. IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex , 2003, Nature Immunology.
[14] M. Ghany,et al. Diagnosis, management, and treatment of hepatitis C: An update , 2009, Hepatology.
[15] M. Shiffman,et al. 643 PEG-IFN-l: ANTIVIRAL ACTIVITY AND SAFETY PROFILE IN A 4-WEEK PHASE 1B STUDY IN RELAPSED GENOTYPE 1 HEPATITIS C INFECTION , 2009 .
[16] X. Mu,et al. Interleukin-29 Functions Cooperatively with Interferon to Induce Antiviral Gene Expression and Inhibit Hepatitis C Virus Replication* , 2008, Journal of Biological Chemistry.
[17] A. Zekry,et al. Treatment responses in Asians and Caucasians with chronic hepatitis C infection. , 2008, World journal of gastroenterology.
[18] Scott R. Presnell,et al. IL-28, IL-29 and their class II cytokine receptor IL-28R , 2002, Nature Immunology.
[19] Manuel A. R. Ferreira,et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.
[20] K. Kowdley,et al. Biting the iron bullet: Endoplasmic reticulum stress adds the pain of hepcidin to chronic liver disease , 2010, Hepatology.
[21] Jacques Fellay,et al. WGAViewer: software for genomic annotation of whole genome association studies. , 2008, Genome research.
[22] P. Bedossa,et al. Intraobserver and Interobserver Variations in Liver Biopsy Interpretation in Patients with Chronic Hepatitis C , 1994 .
[23] T. Asselah,et al. Gene expression and hepatitis C virus infection , 2008, Gut.
[24] K. Johnson. An Update. , 1984, Journal of food protection.
[25] David B. Goldstein,et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus , 2009, Nature.
[26] Ding‐Shinn Chen,et al. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[27] William M. Lee,et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. , 2009, The New England journal of medicine.